ClinVar Miner

Submissions for variant NM_000256.3(MYBPC3):c.3811C>T (p.Arg1271Ter) (rs397516042)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 8
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Laboratory for Molecular Medicine, Partners HealthCare Personalized Medicine RCV000475268 SCV000059270 pathogenic Hypertrophic cardiomyopathy 2019-07-03 criteria provided, single submitter clinical testing The p.Arg1271X variant in MYBPC3 gene has been identified in 6 individuals with HCM and segregated with disease in 1 affected family member (Olivotto 2008, Marston 2009, Lopes 2013, Walsh 2017, LMM data). It was also identified in 1 individual with early onset DCM who carried an additional pathogenic variant in MYBCP3 (LMM data). It has been identified in 2/246124 chromosomes by gnomAD ( and reported in ClinVar (Variation ID #42744). This nonsense variant leads to a premature termination codon at position 1271, which is predicted to lead to a truncated or absent protein. Loss of function of the MYBCP3 gene is an established disease mechanism in autosomal dominant HCM. In summary, this variant meets criteria to be classified as pathogenic for autosomal dominant HCM. ACMG/AMP Criteria applied: PVS1, PM2, PS4_Moderate.
GeneDx RCV000158271 SCV000208206 pathogenic not provided 2019-01-04 criteria provided, single submitter clinical testing p.Arg1271Stop (CGA>TGA): c.3811 C>T in exon 33 of the MYBPC3 gene (NM_000256.3). The R1271X mutation in the MYBPC3 gene has been reported previously in association with HCM (Olivotto I et al., 2008; Marston S et al., 2009) and was absent from 300 ethnically matched control chromosomes (Olivotto et al., 2008). The R1271X mutation is predicted to cause loss of normal protein function either due to production of an abnormal, prematurely truncated protein. Numerous other truncating mutations in the MYBPC3 gene have been reported in association with HCM. In addition, R1271X was not observed in approximately 6,000 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations.In summary, R1271X in the MYBPC3 gene is interpreted as a disease-causing mutation. Mutations in the MYBPC3 gene have been reported in 20%-30% of patients with autosomal dominant familial hypertrophic cardiomyopathy, and have been reported less frequently in patients with autosomal dominant familial dilated cardiomyopathy (Cirino A et al., 2011; Hershberger R et al., 2009). The variant is found in HCM panel(s).
Blueprint Genetics RCV000208264 SCV000264044 likely pathogenic Primary familial hypertrophic cardiomyopathy 2015-02-25 criteria provided, single submitter clinical testing
Invitae RCV000475268 SCV000546415 likely pathogenic Hypertrophic cardiomyopathy 2020-10-15 criteria provided, single submitter clinical testing This sequence change results in a premature translational stop signal in the MYBPC3 gene (p.Arg1271*). While this is not anticipated to result in nonsense mediated decay, it is expected to delete the last 4 amino acids of the MYBPC3 protein. This variant is present in population databases (rs397516042, ExAC 0.009%). This variant has been observed in several individuals affected with hypertrophic cardiomyopathy (HCM) (PMID: 18533079, 19574547, 23396983, 27532257, Invitae) and in one individual affected with dilated cardiomyopathy (DCM) who also carried a different pathogenic variant in MYBPC3 (PMID: 19996403). ClinVar contains an entry for this variant (Variation ID: 42744). Experimental studies have shown that this nonsense change results in undetectable truncated MYBPC3 protein, but with modest reduction of MYBPC3 mRNA by RT-PCR (PMID: 19574547). In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic.
Fulgent Genetics,Fulgent Genetics RCV000515345 SCV000611211 pathogenic Familial hypertrophic cardiomyopathy 4; Left ventricular noncompaction 10 2017-05-18 criteria provided, single submitter clinical testing
Ambry Genetics RCV000621330 SCV000740206 pathogenic Cardiovascular phenotype 2017-08-08 criteria provided, single submitter clinical testing The p.R1271* pathogenic mutation (also known as c.3811C>T), located in coding exon 33 of the MYBPC3 gene, results from a C to T substitution at nucleotide position 3811. This changes the amino acid from an arginine to a stop codon within coding exon 33. This alteration has been reported in individuals with hypertrophic cardiomyopathy (Olivotto I et al. Mayo Clin. Proc., 2008 Jun;83:630-8; Marston S et al. Circ. Res., 2009 Jul;105:219-22; Judge DP. JAMA, 2009 Dec;302:2471-6; Walsh R et al. Genet. Med., 2017 Feb;19:192-203). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.
Center for Advanced Laboratory Medicine, UC San Diego Health,University of California San Diego RCV000852435 SCV000995120 pathogenic Long QT syndrome; Hypertrophic cardiomyopathy 2018-06-05 criteria provided, single submitter clinical testing
CHEO Genetics Diagnostic Laboratory,Children's Hospital of Eastern Ontario RCV001170942 SCV001333593 pathogenic Cardiomyopathy 2018-09-11 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.